In its March meeting the EMA’s human medicines committee recommended five medicines for approval and concluded its review of regdanvimab as a treatment for COVID-19.
List view / Grid view
Multiple Sclerosis (MS)
Filter the results
The European medical cannabis market lacks a common regulatory framework; Peter Kohut charts a route through the complexity and highlights opportunities for the taking.
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
The committee for human medicinal products recommended AstraZeneca’s COVID-19 vaccine be granted conditional marketing authorisation alongside 12 other approvals.
Kesimpta was approved based on trial results showing the monthly injection significantly reduced the relapse rate and disability progression of MS patients compared to a currently approved treatment.
Sanofi is set to acquire Principia Biopharma Inc. for a total aggregate equity value of $3.68 billion, at $100 per share.
Dapivirine Vaginal Ring (dapivirine) and Blenrep (belantamab mafodotin) have been recommended for approval by the EMA's CHMP, along with nine other medicines.
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
A Phase II clinical trial has shown that a two-week course of interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within seven days of showing COVID-19 symptoms, is safe and effective.
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
A study of over 602 brand-name prescription drugs shows that list prices increased over 1.5 times and net prices rose over 3.5 times inflation in the past decade.
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).